SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)PRNewsWire · Oct 12, 2026
Head-To-Head Analysis: Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX)Defense World · Oct 5, 2026
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down – What’s Next?Defense World · Sep 24, 2026
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable ResponsesDefense World · Sep 23, 2026
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria TranscriptSeeking Alpha · Sep 22, 2026
Celldex Prepares For 2027 FDA Submission for Chronic Skin DiseaseBenzinga · Sep 22, 2026Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.06 | -$0.94 | Beat |
| May 7, 2026 | -$1.15 | -$1.18 | Miss |
| Feb 25, 2026 | -$1.00 | -$1.22 | Miss |
| Nov 10, 2025 | -$0.88 | -$1.01 | Miss |
| Aug 7, 2025 | -$0.86 | -$0.85 | Beat |
| May 8, 2025 | -$0.75 | -$0.81 | Miss |